Syngene Partners With Johns Hopkins University to Advance Early-Stage Drug Discovery

Under the agreement, selected discoveries from Johns Hopkins will be progressed through Syngene’s industrial-scale research and development infrastructure.

Syngene International has entered into a strategic collaboration with Johns Hopkins University to accelerate early-stage drug discovery programs and platform technologies originating from the university’s research laboratories. The announcement was made in Hyderabad on February 10.

The collaboration will be anchored in Syngene’s SynVent platform, an integrated drug discovery and development engine that spans discovery biology, medicinal and synthetic chemistry, drug metabolism and pharmacokinetics (DMPK), toxicology, and early development.

Under the agreement, selected discoveries from Johns Hopkins will be progressed through Syngene’s industrial-scale research and development infrastructure.

The initiative will also use Syngene’s Connector model, which links academic research programs with pharmaceutical companies, biotech firms, strategic investors, and downstream licensing opportunities. The model is designed to facilitate the transition of high-potential laboratory research into structured development pathways.

According to the companies, the partnership aims to compress development timelines and improve the likelihood of successful clinical translation. By integrating academic science with commercial drug discovery capabilities, the collaboration seeks to advance promising therapeutic programs toward clinical readiness.

Kenneth Barr, Senior Vice President and Head of Strategic Collaborations at Syngene International, said the agreement expands the company’s global innovation network. “By combining pioneering academic science with our integrated discovery and development capabilities, we aim to significantly reduce the time it takes for high-potential programs to become clinically relevant,” he said.

Paul Nkansah, Senior Director of Corporate Partnerships at Johns Hopkins Technology Ventures, stated that the collaboration would connect discoveries from Johns Hopkins laboratories with Syngene’s drug discovery expertise and broader pharmaceutical and investor networks, potentially accelerating their path toward patient-focused applications.

Further details regarding specific therapeutic areas or financial terms of the collaboration were not disclosed.

Stay tuned for more such updates on Digital Health News